T0318
曲尼司特
≥98% (HPLC), LTC4 inhibitor, powder
别名:
2-[[3-（3,4-二甲氧基苯基）-1-氧代-2-丙烯基] 氨基] 苯甲酸, 3,4-DAA, N-（3,4-二甲氧基肉桂酰）邻氨基苯甲酸, SB-252218, 利喘平
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C18H17NO5
化学文摘社编号:
分子量:
327.33
MDL编号:
UNSPSC代码:
41106500
PubChem化学物质编号:
NACRES:
NA.77
产品名称
曲尼司特, ≥98% (HPLC), powder
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
mp
166.2-168.2 °C (lit.)
溶解性
DMSO: >10 mg/mL
H2O: insoluble
创始人
Kissei
储存温度
2-8°C
SMILES字符串
COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC
InChI
1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+
InChI key
NZHGWWWHIYHZNX-CSKARUKUSA-N
基因信息
human ... VEGFA(7422), VEGFB(7423), VEGFC(7424)
应用
在小鼠骨髓来源的肥大细胞中研究了曲尼司特对肥大细胞表面受体的作用。
生化/生理作用
曲尼司特是一种抗哮喘药物，可抑制刺激单核细胞 LTC 4 和 PGE 2 的形成，但不抑制环氧合酶或脂氧合酶活性；抑制肥大细胞脱颗粒；在体内抑制 VEGF 诱导的血管生成 ，在体外也抑制人内皮细胞的增殖和管道形成 。曲尼司特可能代表一类新的治疗 T H 1 介导的自身免疫性疾病的药物。
曲尼司特是一种抗哮喘药物，抑制刺激的单核细胞 LTC 4 和 PGE 2 的形成，抑制肥大细胞脱颗粒，并抑制体内 VEGF 诱导的血管生成，也抑制体外人内皮细胞的增殖和成管。
曲尼司特还通过抑制细胞周期蛋白依赖性激酶抑制剂-1（p21Waf1 / Cip1）来抑制血管平滑肌细胞的增殖，它可用于治疗心脏同种异体移植物血管病变（cardiac allograft vasculopathy）。它用于治疗肥厚性瘢痕和瘢痕疙瘩。曲尼司特会抑制肿瘤坏死因子（TNF-α和TGF-β2），从而阻碍人视网膜色素上皮细胞系（ARPE）的上皮间质转化。
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral
储存分类代码
11 - Combustible Solids
WGK
WGK 3
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
Noriaki Minami et al.
Cancer medicine, 6(11), 2635-2645 (2017-10-06)
Therapeutic options for malignant brain tumors are limited, with new drugs being continuously evaluated. Organotypic brain slice culture has been adopted for neuroscience studies as a system that preserves brain architecture, cellular function, and the vascular network. However, the suitability
Tranilast inhibits the expression of genes related to epithelial-mesenchymal transition and angiogenesis in neurofibromin-deficient cells
Harigai R, et al.
Scientific reports, 8(1), 6069-6069 (2018)
Venkateswaran Subramaniam et al.
Experimental and molecular pathology, 90(1), 116-122 (2010-11-03)
In the treatment of breast cancer, although a wide of choice of drugs and treatment modalities are available, drug resistance or drug toxicity poses a considerable challenge. Tranilast is a well tolerated drug used in the treatment of allergic disorders.
Md Imran Khan et al.
PloS one, 14(5), e0216427-e0216427 (2019-05-10)
In this report, using NMR and molecular modeling, we have studied the structure of lysozyme-S100A6 complex and the influence of tranilast [N-(3, 4-dimethoxycinnamoyl) anthranilic acid], an antiallergic drug which binds to lysozyme, on lysozyme-S100A6 and S100A6-RAGE complex formation and, finally
Md Soriful Islam et al.
The Journal of clinical endocrinology and metabolism, 99(5), E775-E785 (2014-03-13)
Uterine leiomyomas are highly prevalent benign tumors of premenopausal women and the most common indication for hysterectomy. However, the exact etiology of this tumor is not fully understood. The objective of the study was to evaluate the role of activin-A
商品
Discover Bioactive Small Molecules for Lipid Signaling Research
相关内容
Instructions
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持